中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
14期
48-51
,共4页
冷良%马燕玲%马玉英%郑红俊%冯义柏
冷良%馬燕玲%馬玉英%鄭紅俊%馮義柏
랭량%마연령%마옥영%정홍준%풍의백
别嘌呤醇%高尿酸血症%心肌病,扩张型
彆嘌呤醇%高尿痠血癥%心肌病,擴張型
별표령순%고뇨산혈증%심기병,확장형
Allopurinol%Hyperuricemia%Cardiomyopathy,dilated
目的 探讨别嘌醇对高尿酸血症扩张型心肌病患者心功能的影响.方法 将120例高尿酸血症扩张型心肌病患者根据治疗方法不同分为别嘌醇组和对照组,每组60例.两组患者入院后均给予常规治疗,在此基础上对照组加用硝普钠治疗,而别嘌醇组加用别嘌醇和硝普钠治疗,两组均治疗3个月.结果 别嘌醇组总有效率明显高于对照组[90.0％ (54/60)比75.0％(45/60)],差异有统计学意义(P＜0.05).别嘌醇组治疗后左室射血分数和左室收缩末期后壁厚度明显高于对照组[(67.85±7.12)％比(30.78±7.00)％和(1.40±0.20) mm比(1.16±0.18) mm],而左室收缩末期内径、左室舒张末期内径和左室舒张末期后壁厚度明显低于对照组[(4.72±0.41) mm比(6.48±0.47) mm、(2.93±0.32) mm比(5.56±0.62) mm和(0.77±0.13) mm比(0.92±0.18) mm],差异均有统计学意义(P＜0.05).别嘌醇组治疗后尿酸、尿素氮和肌酐均明显低于对照组[(45.43±11.24)μmol/L比(167.23±19.22) μmol/L、(10.23±7.12) mmol/L比(40.93±8.09) mmol/L和(32.01±8.34) mmol/L比(78.09±9.11) mmol/L],差异均有统计学意义(P＜0.05).结论 别嘌醇在降低高尿酸血症扩张型心肌病患者尿酸的同时,可早期逆转动脉硬化,改善心功能,值得推广应用研究.
目的 探討彆嘌醇對高尿痠血癥擴張型心肌病患者心功能的影響.方法 將120例高尿痠血癥擴張型心肌病患者根據治療方法不同分為彆嘌醇組和對照組,每組60例.兩組患者入院後均給予常規治療,在此基礎上對照組加用硝普鈉治療,而彆嘌醇組加用彆嘌醇和硝普鈉治療,兩組均治療3箇月.結果 彆嘌醇組總有效率明顯高于對照組[90.0％ (54/60)比75.0％(45/60)],差異有統計學意義(P＜0.05).彆嘌醇組治療後左室射血分數和左室收縮末期後壁厚度明顯高于對照組[(67.85±7.12)％比(30.78±7.00)％和(1.40±0.20) mm比(1.16±0.18) mm],而左室收縮末期內徑、左室舒張末期內徑和左室舒張末期後壁厚度明顯低于對照組[(4.72±0.41) mm比(6.48±0.47) mm、(2.93±0.32) mm比(5.56±0.62) mm和(0.77±0.13) mm比(0.92±0.18) mm],差異均有統計學意義(P＜0.05).彆嘌醇組治療後尿痠、尿素氮和肌酐均明顯低于對照組[(45.43±11.24)μmol/L比(167.23±19.22) μmol/L、(10.23±7.12) mmol/L比(40.93±8.09) mmol/L和(32.01±8.34) mmol/L比(78.09±9.11) mmol/L],差異均有統計學意義(P＜0.05).結論 彆嘌醇在降低高尿痠血癥擴張型心肌病患者尿痠的同時,可早期逆轉動脈硬化,改善心功能,值得推廣應用研究.
목적 탐토별표순대고뇨산혈증확장형심기병환자심공능적영향.방법 장120례고뇨산혈증확장형심기병환자근거치료방법불동분위별표순조화대조조,매조60례.량조환자입원후균급여상규치료,재차기출상대조조가용초보납치료,이별표순조가용별표순화초보납치료,량조균치료3개월.결과 별표순조총유효솔명현고우대조조[90.0％ (54/60)비75.0％(45/60)],차이유통계학의의(P＜0.05).별표순조치료후좌실사혈분수화좌실수축말기후벽후도명현고우대조조[(67.85±7.12)％비(30.78±7.00)％화(1.40±0.20) mm비(1.16±0.18) mm],이좌실수축말기내경、좌실서장말기내경화좌실서장말기후벽후도명현저우대조조[(4.72±0.41) mm비(6.48±0.47) mm、(2.93±0.32) mm비(5.56±0.62) mm화(0.77±0.13) mm비(0.92±0.18) mm],차이균유통계학의의(P＜0.05).별표순조치료후뇨산、뇨소담화기항균명현저우대조조[(45.43±11.24)μmol/L비(167.23±19.22) μmol/L、(10.23±7.12) mmol/L비(40.93±8.09) mmol/L화(32.01±8.34) mmol/L비(78.09±9.11) mmol/L],차이균유통계학의의(P＜0.05).결론 별표순재강저고뇨산혈증확장형심기병환자뇨산적동시,가조기역전동맥경화,개선심공능,치득추엄응용연구.
Objective To study the cardiac function effect of allopurinol for hypemricemia combined with dilated cardiomyopathy patients.Methods One hundred and twenty hypemricemia combined with dilated cardiomyopathy patients were divided into allopurinol group and control group according to the treatment method with 60 cases each.All the patients were given conventional treatment,the control group was added the nitroprusside treatment,and the allopurinol group was added the allopurinol and nitroprusside treatment.The treatment period was 3 months.Results The total effective rate in allopurinol group was significantly higher than that in control group [90.0％ (54/60) vs.75.0％ (45/60)],there was statistical difference (P ＜ 0.05).After treatment,the left ventricular ejection fraction and left ventricular posterior wall thickness at end-systole in allopurinol group were significantly higher than those in control group [(67.85 ± 7.12)％ vs.(30.78 ±7.00)％ and (1.40 ±0.20) mm vs.(1.16 ±0.18) mm[,but the left ventricular internal diameter at end-systole,left ventricular internal diameter at end-diastole and left ventricular posterior wall thickness at end-diastole were significantly lower than those in control group [(4.72 ± 0.41) mm vs.(6.48 ± 0.47) mm,(2.93 ± 0.32) mm vs.(5.56 ± 0.62) mm and (0.77 ± 0.13) mm vs.(0.92 ± 0.18) mm],there were statistical differences (P ＜ 0.05).After treatment,The uric acid,urea nitrogen and creatinine were significantly lower than those in control group [(45.43 ± 11.24) μ mol/L vs.(167.23 ± 19.22) μ mol/L,(10.23 ± 7.12)mmol/L vs.(40.93 ± 8.09)mmol/L and (32.01 ± 8.34) mmol/L vs.(78.09 ±9.11) mmol/L],there were statistical differences (P ＜ 0.05).Conclusion Allopurinol used for treating hyperuricemia combined with dilated cardiomyopathy patients can reduce uric acid,early reversal the atherosclerosis and improve heart function,it should be widely applied research.
